Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK

Abstract

Background: Skin toxicity is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the correlation between skin toxicity and the efficacy of Cmab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).Methods: We retrospectively reviewed 112 R/M SCCHN patients who received palliative chemotherapy with Cmab. Main eligibility criteria included primary disease in the oral cavity, hypopharynx, nasopharynx, oropharynx, or larynx; no prior history of EGFR-directed therapy; receipt of Cmab plus chemotherapy as first-line therapy for recurrent or metastatic disease; and follow-up for more than 90 days. We analyzed the time to first occurrence and time of maximum grade skin toxicity, and its predictive value with regard to treatment efficacy.Results: After a median follow-up of 393 days (range 109–1501 days), 105 (94%) and 20 (18%) patients had skin toxicity of any grade and grade 3, respectively. Among them, 8 patients with grade 3 acneiform rash, skin rash, or paronychia within 90 days after treatment initiation (“early skin toxicity”) had improved progression-free survival (PFS) (log-rank test, P = 0.045; 2-year PFS, 25.0 vs. 2.9%) and overall survival (OS) (log-rank test, P = 0.023, 2-year OS, 50.0 vs. 14.4%) compared with those with < grade 3 toxicity. A greater proportion of patients with early skin toxicity than patients without this toxicity could proceed with Cmab maintenance (88 vs. 44%, P = 0.021). Multivariate analysis identified early skin toxicity as an independent predictor of better PFS (hazard ratio [HR] = 0.363, 95% confidence interval [CI] 0.142–0.924, P = 0.034) and OS (HR = 0.187, 95% CI: 0.045–0.781, P = 0.022).Conclusion: Grade 3 Cmab-induced skin toxicity within 90 days was associated with better survival in R/M SCCHN. Effective rash management therefore seems necessary to realize the benefit of Cmab treatment.

Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

“…Common adverse events. PFS of 3.9-7.7 months, and median OS of 7.6-16.8 months(8)(9)(10)(11)(12)(13)(14)(15)(16). The results of our study are consistent with those of previous studies.…”

“…Recently, the combination of taxanes and Cmab, for example, exchanging 5-FU for taxanes in the Extreme regimen, has drawn attention (7). Cmab and paclitaxel combination therapy (Cmab-PTX), first reported by Hitt et al (8), is one such combination, and some studies have reported that Cmab-PTX has good efficacy for R/MHNSCC patients (7)(8)(9)(10)(11)(12)(13)(14)(15)(16). However, the prognostic factors associated with Cmab-PTX have been inadequately reported (9,10).…”

Unseiin, a Kampo medicine, Reduces the Severity and Manifestations of Skin Toxicities Induced by Cetuximab: A Case Report

“…15,16 However, occurrence of more severe Cmabinduced skin toxicity is correlated with better treatment response and longer survival in several studies across multiple malignancies. 12,17,18 Cmab therapy should be continued if it has a therapeutic effect. Therefore, it is important to manage skin toxicities such as paronychia and skin fissures because treatment interruption and discontinuation due to the severity of skin toxicity should be avoided in order to achieve maximum benefit.…”

The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials

“…Survival was computed from the landmark (39). Similarly an analysis of the predictive value of cetuximab-induced skin toxicity in recurrent or metastatic head and neck cancer was conducted using the landmark method applied to PFS and OS counted from 90 days after the start of therapy (40).…”